

PTO/SB/08a SUBSTITUTE FOR FORM PTO-1449A INFORMATION DISCLOSURE STATEMENT BY APPLICANT	DOCKET NO. 00395/61	SERIAL NO. 10/541,263
	APPLICANT Housey et al.	CONFIRMATION NO. 6621
	FILING DATE April 18, 2006	GROUP 1649

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	US 2002/0098169	7/25/2002	Smith			
	US 2001/0012829	8/9/2001	Anderson et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Abstract only	
						YES	NO
	DE 19921537 (A1)	11/23/2000	Germany			X	

OTHER DOCUMENTS

EXAMINER INITIAL	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	BURKS, D.J. et al., IRS-2 pathways integrate female reproduction and energy homeostasis. Nature, Vol. 407, September 21, 2000, pp 377-382.	
	GREIG, N.II. et al., Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia, (1999) Vol. 42, pp 45-50.	
	PERRY, T.A. et al., The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. Journal of Alzheimer's Disease (2002) Vol. 4, pp 487-496.	
	VAßEN, L. et al. Human Insulin Receptor Substrate-2. Diabetes, Vol. 48, September 1999, pp 1877-1880.	
	ZANDER, M. et al., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and B-cell function in type 2 diabetes: a parallel-group study, The Lancet, Vol 359 March 9, 2002, pp 824-830.	
EXAMINER	/Christina Borgeest/ (11/04/2009)	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		